// App-Quantinova.ai

LB0001 : EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PsA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • J. Anderson

  • M. Magrey

  • J. F. Merola

  • Y. Liu

  • M. Kishimoto

  • S. Jeka

  • C. F. Pacheco Tena

  • X. Wang

  • L. Chen

  • P. Zueger

  • A. Pangan

  • F. Behrens

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Case Western Reserve University, School of Medicine, MetroHealth Medical Center, Cleveland, Ohio, United States

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Dept of Rheumatology, W China Hospital, Sichuan Univ, Sichuan, China

  • Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

  • Dept of Rheumatology and Connective Tissue Diseases, 2nd Univ Hospital, Bydgoszcz, Poland

  • Facultad de Medicina, Universidad Autonoma de Chihuahua, Chihuahua, Mexico

  • Goethe University & Fraunhofer IME-TMP and CIMD, Frankfurt, Germany

Locations

  • United Kingdom

  • United States

  • China

  • Japan

  • Poland

  • Mexico

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

  • Nutritional risk screening

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

  • Non Inferiority

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Amgen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved